Targeting of Drugs 6

The NATO Advanced Studies Institute series "Targeting of Drugs" was originated in 1981. It is now a major international forum, held every two years in Cape Sounion, Greece, in which the present and the future of this important area of research in drug delivery is discussed in great depth. Previous ASIs of the series dealt with drug carriers of natural and synthetic origin, their interactions with the biological milieu, ways by which milieu interference is circumvented, approaches to carrier design or modification that contribute to optimal carrier function, and, more recently, with strategies for gene and oligonucleotide delivery in therapy The present book contains the proceedings of the 9th NATO ASI, "Targeting of Drugs: Strategies for Stealth Therapeutic Systems", held in Cape Sounion during 24 June -5 July 1997. As the title implies, the book deals with a variety of approaches to evade the reticuloendothelial system and thus extend the circulation time of a variety of delivery systems including polymers, biopolymers, liposomes, and other nanoparticles or microparticles. We express our appreciation to Mrs. Concha Perring for her assistance with the organization of the AS!. The ASI was held under the sponsorship of NATO Scientific Affairs Division and supported by Sequus Pharmaceuticals (Menlo Park, CA, USA), The Liposome Company (Princeton, NJ, USA), NOVO Nordisk (Bagsvaard, Denmark), NeXstar Pharmaceuticals (Boulder, CO, USA), Gene Medicine (Houston, TX, USA), Pfizer Ltd (Sandwich, Kent, UK), Merck (Rahway, NJ, USA), and Biovation Ltd (Aberdeen, UK).

Klappentext

Proceedings of a NATO ASI held in Cape Sounion Beach, Greece, June 24-July 5, 1997

Zusammenfassung
Proceedings of a NATO ASI held in Cape Sounion Beach, Greece, June 24-July 5, 1997

Inhalt
Interactions between Blood Components and Artificial Surfaces.- The Mononuclear Phagocyte System: Features Relevant to Interactions with Liposomes.- Stealth™ Therapeutic Systems: Rationale and Strategies.- Long Circulating Liposomes: Evolution of the Concept.- Sterically Stabilized Immunoliposomes: Formulations for Delivery of Drugs and Genes to Tumor Cells in Vivo..- Pegylation of Liposomes in Cell-Specific Targeting: It Does Not Always Make Sense.- Stealth™ Liposomes for the Targeting of Drugs in Cancer Therapy.- Stealth™ Liposomes as Carriers of Doxorubicin.- Liposome-Mediated Delivery of Retinoids.- Applications of Liposome Technology to Overcome Multidrug Resistance in Solid Tumors.- Use of Radiolabeled Liposomes for PEG-Liposome-Based Drug Targeting and Diagnostic Imaging Applications.- Diagnostic and Therapeutic Targeting of Infectious and Inflammatory Diseases Using Sterically Stabilized Liposomes.- Biologically Active Ligand-Bearing Polymer-Grafted Liposomes.- Engineering Stealth™ Liposome Surfaces: Exercises in Colloid Chemistry Principles.- The Role of Hydration in Stabilization of Liposomes: Resistance to Oxidative Damage of PEG-Grafted Liposomes.- Physicochemical Characterization of DOTAP-Containing Lipoplexes by Fluorescent Probes: Relevance to Lipofection.- Steric Stabilization of Cationic Liposome-DNA Complexes: Influence on Morphology and Transfection Activity.- Polysialic Acids: Potential for Long Circulating Drug, Protein, Liposome and Other Microparticle Constructs.- Tailor-Made Soluble Polymer Carriers.- Development of Novel Technologies for the Synthesis of Biodegradable Pegylated Nanoparticles.- Development of a New Class of Nanoparticles which Avoid Phagocytosis by Inhibiting Complement Activation.- Coating of Nanoparticles withSurfactants: Targeting versus Prolonged Circulation.- Recent Developments and Limitations of Poloxamine-Coated Long-Circulating Particles in Experimental Drug Delivery.- PEG-Coated Nanospheres: Surface Optimization and Therapeutic Applications.- Participants' Photograph.- Contributors.